Cost-effectiveness analysis of treatment modalities for women with high-intermediate risk endometrial carcinoma: Should Gynecologic Oncology Group (GOG) 249 have included a chemotherapy-only arm?

E.E. Landers; R.C. Arend; J.M. Straughn; C.A. Leath

doi:10.1016/J.YGYNO.2014.03.372

Cost-effectiveness analysis of treatment modalities for women with high-intermediate risk endometrial carcinoma: Should Gynecologic Oncology Group (GOG) 249 have included a chemotherapy-only arm?

E.E. Landers
, R.C. Arend
, J.M. Straughn
, C.A. Leath

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Gynecologic Oncology
Volume	133
DOIs	https://doi.org/10.1016/J.YGYNO.2014.03.372
State	Published - Jun 1 2014

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1016/J.YGYNO.2014.03.372License: Unspecified

Cite this

@article{15b15d1c3c80480b9a1c7601ea398885,

title = "Cost-effectiveness analysis of treatment modalities for women with high-intermediate risk endometrial carcinoma: Should Gynecologic Oncology Group (GOG) 249 have included a chemotherapy-only arm?",

author = "E.E. Landers and R.C. Arend and J.M. Straughn and C.A. Leath",

note = "West Exhibit Hall (Tampa Convention Center) E. E. Landers, R. C. Arend, J. M. Straughn Jr. and C. A. Leath III University of Alabama at Birmingham, Birmingham, AL",

year = "2014",

month = jun,

day = "1",

doi = "10.1016/J.YGYNO.2014.03.372",

language = "American English",

volume = "133",

journal = "Gynecologic Oncology",